Cargando…

Treatment options for acute myeloid leukemia patients aged <60 years

Treatment of acute myeloid leukemia (AML) has changed over the last few years, after the discovery of new drugs selectively targeting AML blasts. Although 3/7 remains the standard of care for most AML patients, several new targeted agents (such as FLT3 inhibitors, CPX-351, gemtuzumab ozogamicin, BCL...

Descripción completa

Detalles Bibliográficos
Autores principales: Visani, Giuseppe, Chiarucci, Martina, Paolasini, Sara, Loscocco, Federica, Isidori, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9581198/
https://www.ncbi.nlm.nih.gov/pubmed/36276074
http://dx.doi.org/10.3389/fonc.2022.897220
_version_ 1784812565681930240
author Visani, Giuseppe
Chiarucci, Martina
Paolasini, Sara
Loscocco, Federica
Isidori, Alessandro
author_facet Visani, Giuseppe
Chiarucci, Martina
Paolasini, Sara
Loscocco, Federica
Isidori, Alessandro
author_sort Visani, Giuseppe
collection PubMed
description Treatment of acute myeloid leukemia (AML) has changed over the last few years, after the discovery of new drugs selectively targeting AML blasts. Although 3/7 remains the standard of care for most AML patients, several new targeted agents (such as FLT3 inhibitors, CPX-351, gemtuzumab ozogamicin, BCL-2 inhibitor, and oral azacitidine), either as single agents or combined with standard chemotherapy, are approaching clinical practice, starting a new era in AML management. Moreover, emerging evidence has demonstrated that high-risk AML patients might benefit from both allogeneic stem cell transplant and maintenance therapy, providing new opportunities, as well as new challenges, for treating clinicians. In this review, we summarize available data on first-line therapy in young AML patients focusing on targeted therapies, integrating established practice with new evidence, in the effort to outline the contours of a new therapeutic paradigm, that of a “total therapy”, which goes beyond obtaining complete remission.
format Online
Article
Text
id pubmed-9581198
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95811982022-10-20 Treatment options for acute myeloid leukemia patients aged <60 years Visani, Giuseppe Chiarucci, Martina Paolasini, Sara Loscocco, Federica Isidori, Alessandro Front Oncol Oncology Treatment of acute myeloid leukemia (AML) has changed over the last few years, after the discovery of new drugs selectively targeting AML blasts. Although 3/7 remains the standard of care for most AML patients, several new targeted agents (such as FLT3 inhibitors, CPX-351, gemtuzumab ozogamicin, BCL-2 inhibitor, and oral azacitidine), either as single agents or combined with standard chemotherapy, are approaching clinical practice, starting a new era in AML management. Moreover, emerging evidence has demonstrated that high-risk AML patients might benefit from both allogeneic stem cell transplant and maintenance therapy, providing new opportunities, as well as new challenges, for treating clinicians. In this review, we summarize available data on first-line therapy in young AML patients focusing on targeted therapies, integrating established practice with new evidence, in the effort to outline the contours of a new therapeutic paradigm, that of a “total therapy”, which goes beyond obtaining complete remission. Frontiers Media S.A. 2022-10-05 /pmc/articles/PMC9581198/ /pubmed/36276074 http://dx.doi.org/10.3389/fonc.2022.897220 Text en Copyright © 2022 Visani, Chiarucci, Paolasini, Loscocco and Isidori https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Visani, Giuseppe
Chiarucci, Martina
Paolasini, Sara
Loscocco, Federica
Isidori, Alessandro
Treatment options for acute myeloid leukemia patients aged <60 years
title Treatment options for acute myeloid leukemia patients aged <60 years
title_full Treatment options for acute myeloid leukemia patients aged <60 years
title_fullStr Treatment options for acute myeloid leukemia patients aged <60 years
title_full_unstemmed Treatment options for acute myeloid leukemia patients aged <60 years
title_short Treatment options for acute myeloid leukemia patients aged <60 years
title_sort treatment options for acute myeloid leukemia patients aged <60 years
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9581198/
https://www.ncbi.nlm.nih.gov/pubmed/36276074
http://dx.doi.org/10.3389/fonc.2022.897220
work_keys_str_mv AT visanigiuseppe treatmentoptionsforacutemyeloidleukemiapatientsaged60years
AT chiaruccimartina treatmentoptionsforacutemyeloidleukemiapatientsaged60years
AT paolasinisara treatmentoptionsforacutemyeloidleukemiapatientsaged60years
AT loscoccofederica treatmentoptionsforacutemyeloidleukemiapatientsaged60years
AT isidorialessandro treatmentoptionsforacutemyeloidleukemiapatientsaged60years